Navigating the Waters of Intellectual Property: A Closer Look at the FTC's Patent Listing Policy
The Federal Trade Commission’s new Patent Listing Policy challenges the practice of listing potentially irrelevant patents in the FDA’s Orange Book, which can delay generic drug approvals through automatic 30‑month stays. The policy seeks to curb practices viewed as anticompetitive, with FDA support, though effective enforcement and determining improper listings present challenges. The FTC aims to enhance competition and protect consumers by ensuring accuracy and transparency in pharmaceutical patent listings.
Style rédactionnelÉquilibré
Mix of factual explanation and interpretive commentary on regulatory impact



